Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Mirova US LLC

Mirova US LLC lessened its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 2.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,809,222 shares of the medical research company's stock after selling 53,910 shares during the period. Edwards Lifesciences makes up 1.6% of Mirova US LLC's investment portfolio, making the stock its 25th largest holding. Mirova US LLC owned 0.31% of Edwards Lifesciences worth $133,937,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EW. Abacus Planning Group Inc. grew its holdings in Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock valued at $2,977,000 after purchasing an additional 140 shares during the period. Bowman & Co S.C. lifted its position in shares of Edwards Lifesciences by 1.2% during the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock worth $924,000 after purchasing an additional 148 shares in the last quarter. Moors & Cabot Inc. lifted its position in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after purchasing an additional 152 shares in the last quarter. Pegasus Asset Management Inc. increased its stake in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock worth $3,156,000 after buying an additional 159 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC increased its stake in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company's stock worth $634,000 after buying an additional 162 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Remove Ads

Analysts Set New Price Targets

EW has been the subject of several recent research reports. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Barclays upped their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Evercore ISI cut their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Morgan Stanley boosted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group upped their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $79.95.

Edwards Lifesciences Stock Down 0.7 %

Shares of NYSE:EW traded down $0.50 during mid-day trading on Friday, hitting $70.46. 7,144,270 shares of the company traded hands, compared to its average volume of 4,607,998. The stock has a 50-day moving average price of $71.42 and a two-hundred day moving average price of $70.36. The stock has a market cap of $41.42 billion, a P/E ratio of 10.11, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Steven R. Loranger sold 5,739 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now directly owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares in the company, valued at approximately $1,569,414.24. This represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,303 shares of company stock worth $3,715,776 in the last 90 days. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.